Outcomes of Patients With Neovascular Age-Related Macular Degeneration (Namd) In Greece Under Ranibizumab
نویسندگان
چکیده
منابع مشابه
Ranibizumab in neovascular age-related macular degeneration
BACKGROUND Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration. METHODS In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular degeneration with either minima...
متن کاملMacular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Background Vascular endothelial growth factor (VEGF) is considered to play an essential role in the pathogenesis of agerelated macular degeneration due to its vascular permeability-inducing and angiogenic properties. Ranibizumab, a small antibody fragment designed to competitively bind all VEGF isoforms, passes after intravitreal injection into all retinal layers reaching the retinal pigment ep...
متن کاملCost-effectiveness of ranibizumab for neovascular age-related macular degeneration
BACKGROUND Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain. METHODS We assessed the cost-effectiveness of ranibizumab compared with no ranibizumab over 10 years, using randomized trial efficacy data for the first 2 years, post-trial efficacy ass...
متن کاملRanibizumab versus verteporfin for neovascular age-related macular degeneration.
BACKGROUND We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. METHODS During the first year of this 2-year, multicenter, double-blind study, we randomly assigned pat...
متن کاملRanibizumab and bevacizumab for neovascular age-related macular degeneration.
BACKGROUND Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. METHODS In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal inj...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2014
ISSN: 1098-3015
DOI: 10.1016/j.jval.2014.08.2102